Shares of ICU Medical Inc. (NASDAQ:ICUI) were down 1.3% during mid-day trading on Monday . The company traded as low as $108.51 and last traded at $111.22, with a volume of 59,633 shares. The stock had previously closed at $112.74.

A number of analysts have issued reports on ICUI shares. Piper Jaffray Cos. reaffirmed a “neutral” rating and issued a $110.00 target price on shares of ICU Medical in a research note on Saturday, April 23rd. Zacks Investment Research downgraded ICU Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, April 5th.

The stock has a 50 day moving average price of $108.88 and a 200 day moving average price of $101.00. The company has a market capitalization of $1.81 billion and a price-to-earnings ratio of 36.52.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Tuesday, May 10th. The company reported $1.14 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.01 by $0.13. During the same period in the previous year, the firm posted $0.60 EPS. The company earned $89.90 million during the quarter, compared to analyst estimates of $88.04 million. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. On average, analysts anticipate that ICU Medical Inc. will post $4.43 earnings per share for the current fiscal year.

In related news, Director Robert S. Swinney sold 1,875 shares of the company’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $101.40, for a total transaction of $190,125.00. Following the transaction, the director now owns 19,633 shares of the company’s stock, valued at $1,990,786.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Steven Riggs sold 20,000 shares of the company’s stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $110.00, for a total value of $2,200,000.00. Following the transaction, the vice president now directly owns 21,378 shares in the company, valued at approximately $2,351,580. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have made changes to their positions in the company. Marshall Wace LLP raised its position in shares of ICU Medical by 126.6% in the fourth quarter. Marshall Wace LLP now owns 114,554 shares of the company’s stock worth $12,920,000 after buying an additional 64,003 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of ICU Medical by 4.8% in the fourth quarter. Principal Financial Group Inc. now owns 272,927 shares of the company’s stock worth $30,781,000 after buying an additional 12,453 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its position in shares of ICU Medical by 73.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 13,586 shares of the company’s stock worth $1,533,000 after buying an additional 5,742 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of ICU Medical by 0.7% in the fourth quarter. New York State Common Retirement Fund now owns 42,070 shares of the company’s stock worth $4,745,000 after buying an additional 285 shares in the last quarter. Finally, Comerica Bank raised its position in shares of ICU Medical by 2.4% in the fourth quarter. Comerica Bank now owns 14,938 shares of the company’s stock worth $1,550,000 after buying an additional 348 shares in the last quarter.

ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and innovative hemodynamic monitoring systems.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.